𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Optimizing Biochemical Markers as Endpoints for Clinical Trials in Primary Biliary Cirrhosis

✍ Scribed by Momah, Njideka ;Silveira, Marina ;Jorgensen, Roberta A. ;Sinakos, Emmanouil ;Lindor, Keith D.

Book ID
122308766
Publisher
Elsevier Science
Year
2011
Tongue
English
Weight
50 KB
Volume
140
Category
Article
ISSN
0016-5085

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

American association for the study of li
American association for the study of liver diseases endpoints conference: Design and endpoints for clinical trials in primary biliary cirrhosis
✍ Marina G. Silveira; Elizabeth M. Brunt; Jenny Heathcote; Gregory J. Gores; Keith πŸ“‚ Article πŸ“… 2010 πŸ› John Wiley and Sons 🌐 English βš– 143 KB πŸ‘ 1 views

A group of multidisciplinary experts on primary biliary cirrhosis (PBC) and its complications convened on May 31, 2009, under the aegis of the American Association for the Study of Liver Diseases (AASLD) in order to identify the most appropriate design and endpoints for clinical trials of PBC based

Serum hyaluronate in primary biliary cir
Serum hyaluronate in primary biliary cirrhosisβ€”A biochemical marker for progressive liver damage
✍ Anders Nyberg; Anna EngstrΓΆm-LΓ urent; Lars LΓΆΓΆf πŸ“‚ Article πŸ“… 1988 πŸ› John Wiley and Sons 🌐 English βš– 514 KB

To evaluate serum hyaluronate as a marker for progressive liver injury in patients with primary biliary cirrhosis, a longitudinal study including 48 patients was conducted with a mean follow-up time of 40 months. The patients were examined every 6 months with a standardized set of conventional liver